A partial agonist at 5-HT1A, 5-HT1B, and 5-HT2B receptors (Kis = 40, 52, and 81 nM, respectively) decreases aggressive behavior in resident-intruder tests with rats (ID<sub>50</sub> = 0.24 mg/kg).
A partial agonist at 5-HT1A, 5-HT1B, and 5-HT2B receptors (Kis = 40, 52, and 81 nM, respectively) decreases aggressive behavior in resident-intruder tests with rats (ID<sub>50</sub> = 0.24 mg/kg).
A uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout inhibits degranulation of platelets, reducing the release of ADP and thromboxane and
A uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout inhibits degranulation of platelets, reducing the release of ADP and thromboxane and
A uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout inhibits degranulation of platelets, reducing the release of ADP and thromboxane and
A uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout inhibits degranulation of platelets, reducing the release of ADP and thromboxane and